SGLT2 inhibition in CKD: Discussing the key questions and evidence
Meeting report with presentation slides, video and online CME of a PACE-CME symposium held during ERA-EDTA 2019 in Budapest, Hungary on the role of SGLT2i in kidney disease
1
Episodes 1-3 of 3
- SGLT2 inhibition in CKD: Discussing the key questions and evidenceOutcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?
Rajiv Agarwal, MD
- SGLT2 inhibition in CKD: Discussing the key questions and evidenceUnderlying mechanisms of nephroprotective effects with SGLT2i in CKD
Paola Fioretto, MD
- SGLT2 inhibition in CKD: Discussing the key questions and evidenceThe clinical landscape of managing patients with CKD: Where are we now and what can we expect?
Will Herrington, MD
